This triple combination of belimumab, a BAFF-neutralizing antibody which is FDA-approved for systemic lupus erythematosus (SLE), venetoclax and rituximab prevented BAFF-induced venetoclax resistance in CLL in vitro [76]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.